Status:
COMPLETED
Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
High-grade Glioma
Astrocytoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
18F-Fluorothymidine is a recently developed PET tracer to image tumor cell proliferation. Very few data report an interest of using such a tracer for cerebral malignant tumor management. In our projec...
Detailed Description
* Background: 18FDG is the most widely used tracer for oncologic positron emission tomography (PET). However, the high glucose utilization of normal gray matter limits its utility in brain exploration...
Eligibility Criteria
Inclusion
- patients over 18
- suspicion of malignant glioma on MRI aspect
- surgical indication with neuronavigation
- signed informed consent
- absence of contraindication for MRI
- absence of pregnancy or breast-feeding
Exclusion
- women : pregnancy or breast-feeding or no oral or intra-uterine contraception (if not post-menopause)
- secondary exclusion if high grade glioma diagnostic (glioblastoma or astrocytoma grade III) is not confirmed after surgery with histopathology
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00624728
Start Date
February 1 2008
End Date
November 1 2011
Last Update
May 4 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital St André, CHU de Bordeaux
Bordeaux, France, 33000
2
Hôpital Pellegrin-tripode , CHU de Bordeaux
Bordeaux, France, 33076